Transient tissue ‘priming’ via FAK inhibition to impair pancreatic cancer progression and improve sensitivity to gemcitabine/Abraxane [ 2018 - ]

Research Grant

Researchers: Dr Thomas Cox (Principal investigator) ,  A/Pr Paul Timpson

Brief description The success of cancer drugs is dependent on many factors including the properties of the tumour tissue. As a tumour grows it changes the tissue around it, and this affects response to treatment. Combining classical biology with engineering to generate 3D models that mimic tumours, along with cutting-edge imaging technology and mouse models, we will target FAK-controlled cancer cell pathways that sense tissue changes, together with already approved cancer drugs to improve patient outcome.

Funding Amount $643,848.00

Funding Scheme Project Grants

Notes Standard Project Grant